Impact of therapeutic plasma exchange on acquired vaccinal anti-SARS-CoV-2 antibodies.
(2022) European Journal of Internal Medicine — Vol. 100, p. 140-142 (2022)
Files
LambertCetalImpactoftherapeuticplasmaexchangeonacquiredvaccinalanti-SARS-CoV-2antibodies.pdf
Open Access - Adobe PDF
- 382.59 KB
Details
- Authors
- Abstract
- (en) DEAR EDITOR, As of December 2021, more than 276 million affected cases and 5 million deaths were reported by the World Health Organization, due to the COVID-19 pandemic. Following the outbreak's beginning, patients receiving treatments impairing their immunity (e.g., chemotherapy; immunosuppressive drugs for solid organ transplantation or inflammatory diseases) were soon recognized as being at increased risk of developing severe forms of COVID-19. Although anti-SARS-CoV-2 vaccines have proven to be efficacious in reducing the risk of both severe disease and mortality in the general population, emerging evidence has revealed that immunocompromized patients actually display a reduction in vaccine-induced humoral responses. To our best knowledge, the impact of therapeutic plasma exchange (TPE) on anti-SARS-CoV-2 vaccines responses has not yet been investigated so far. [...]
- Affiliations
Citations
Lambert, C., Scohy, A., Yombi, J. C., Goffin, E., & Devresse, A. (2022). Impact of therapeutic plasma exchange on acquired vaccinal anti-SARS-CoV-2 antibodies. European Journal of Internal Medicine, 100, 140-142. https://doi.org/10.1016/j.ejim.2022.02.014 (Original work published 2022)